Enacts new Article 6E, Review of Rare Disease Bills and Resolutions, in GS Chapter 120. Requires that every bill and resolution introduced in the General Assembly that proposes changes to the law pertaining to rare diseases, rare disease research, or rare disease care include an advisory note prepared by the Advisory Council on Rare Diseases (Advisory Council). Specifies that the advisory note must include the Advisory Council's opinion about the merits of the legislation and any recommended changes. Requires the Advisory Council to give the advisory note to the bill sponsor within two weeks after the sponsor has made the request for an advisory note, unless the sponsor agrees to more time. Requires that the advisory note be attached to the original of each proposed bill or resolution that is reported favorably by a committee, but specifies that the note is not a part of the legislation and is not an expression of legislative intent proposed by the legislation. Requires that if a committee reports favorably a proposed bill or resolution with an amendment that proposes a change in the law that pertains to rare diseases, rare disease research, or rare disease care, the chairperson of the committee must obtain an advisory note from the Advisory Council and attach it to the amended bill or resolution. Requires that copies the advisory notes be given to the sponsor of the bill or resolution and the chairpersons of the rules committees.

Makes conforming changes toGS 130A-33.66 by adding the review of each proposed bill and resolution pertaining to rare diseases, rare disease research, and rare disease care and the preparation of an advisory note within 14 days to the Advisory Council's duties. 

Appropriates $250,000 for 2017-18 and $250,000 for 2018-19 from the General Fund to the Department of Health and Human Services to be allocated to the Advisory Council to prepare advisory notes.

Effective July 1, 2017.